The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
---- Acknowledgements ----
We thank Abigail Alpert, Tamara Hayford, and Patrick Healy for outstanding research assistance. We are also grateful to Steve Berry, Jay Bhattacharya, Judith Chevalier, Judith Hellerstein, Melissa Kearney, Jeanne Lafortune, and seminar participants at Columbia, Duke, Maryland, Stanford, Syracuse, Toulouse, the NBER, the Centers for Medicare and Medicaid Services, and the 2008 AEA meetings for helpful comments. We are grateful to Merck and Co. for providing us IMS data, and to IMS for giving permission for us to use their data. This project was supported by National Science Foundation Research Grant 0518858 "The Effect of Government Procurement of Pharmaceuticals." The opinions contained herein are those of the authors and not necessarily of any funding agency. Copyright held by Mark Duggan and Fiona Scott Morton. Contact information for authors: email@example.com, firstname.lastname@example.org. All errors are our own. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research.